Alto Neuroscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ANRO New York 2834 www.altoneuroscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alto Neuroscience, Inc.

Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price - Feb 5th, 2026 4:20 am
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Feb 3rd, 2026 6:27 am
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Jan 14th, 2026 5:27 am
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology - Jan 13th, 2026 6:00 am
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company - Dec 26th, 2025 6:36 am
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Dec 3rd, 2025 2:05 pm
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? - Nov 14th, 2025 7:40 am
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Nov 12th, 2025 5:57 am
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days - Nov 11th, 2025 6:55 am
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - Nov 10th, 2025 9:21 am
How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99% - Nov 10th, 2025 7:55 am
Alto Neuroscience to Participate in Upcoming Investor Conferences - Oct 28th, 2025 5:34 am
Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy - Oct 23rd, 2025 10:00 am
Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect? - Oct 23rd, 2025 7:55 am
Alto shares double on plans to speed depression drug’s development - Oct 20th, 2025 8:50 am
Alto Neuroscience Announces $50 Million Private Placement Financing - Oct 20th, 2025 5:03 am
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting - Oct 20th, 2025 5:01 am
Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia - Oct 17th, 2025 7:27 am
Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate - Oct 6th, 2025 6:45 am
3 Penny Stocks With Market Caps Over $5M To Watch - Oct 3rd, 2025 6:04 am